Candel Therapeutics Appoints Maria Ostrovsky as General CounselGlobeNewsWire · 4 days ago
Candel Therapeutics to Present at the SITC 2026 Annual MeetingGlobeNewsWire · Oct 2, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 1, 2026
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICIGlobeNewsWire · Oct 1, 2026
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate CancerGlobeNewsWire · Sep 30, 2026
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026GlobeNewsWire · Sep 30, 2026Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.24 | -$0.52 | Miss |
| May 14, 2026 | -$0.22 | -$0.14 | Beat |
| Mar 12, 2026 | -$0.24 | -$0.54 | Miss |
| Nov 13, 2025 | -$0.17 | -$0.21 | Miss |
| Aug 14, 2025 | -$0.17 | -$0.09 | Beat |
| May 13, 2025 | -$0.24 | $0.13 | Beat |